Clinical Immunology Communications is a new online only, open-access journal that publishes high-quality, peer-reviewed contributions in the evolving areas of clinical immunology.The journal considers submissions transferred from Clinical Immunology, as well as direct submissions on basic, translational and clinical studies in vitro and in vivo in animal models and in humans, to advance the understanding of cellular, biochemical and molecular aspects of clinical immunology for broad audiences.The ultimate goal of Clinical Immunology Communications is to provide readers with new information on a wide range of clinical immunology subjects including: (1) autoimmune diseases; (2) hypersensitivity and allergy; (3) tumor immunology; (4) immunodeficiencies; (5) immunity to infection including HIV; (6) vaccines; (7) transplantation; (8) new immunological methods and techniques. The types of manuscripts considered for publication will include: (1) original articles; (2) brief communications; (3) reviews; (4) case reports or case cohorts; (5) editorials (by invitation only); (6) guidelines (written by academic authorities and focusing on clinical diagnosis and/or treatment, or use of methodologies in clinical immunology).
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions. • Studies on the nature and function of drug and hormone receptors on lymphocytes and other cells in the immune system.• Studies of cell-derived or humoral factors that modify the immune system causing cytotoxicity, inducing antibody production and mediating inflammatory responses. • The development of immunologically based assays and their application to disease, including assays for drugs, hormones, cyclic nucleotides, tumor antigens, etc. • The Editors will be pleased to receive published books for possible independent review.Please Bookmark this URL: https://www.elsevier.com/locate/intimp These Backfiles include Immunopharmacology and the International Journal of Immunopharmacology .
Official journal of the International Society of Antimicrobial ChemotherapyThe International Journal of Antimicrobial Agents provides comprehensive and up-to-date peer reviewed reference information on the physical, pharmacological, in vitro and clinical properties of individual antimicrobial agents (antiviral agents, antiparasitic agents, antibacterial agents, antifungal agents, etc.). In addition, the journal signals new trends and developments in the field through highly authoritative review articles on antimicrobial agents. Special attention is given to articles providing insight into the problems of antimicrobial resistance both in the hospital and in the community. Both solicited reviews by top experts in the mentioned fields and high-quality original research papers are published.Additional information on the ISAC and its activities can be found at the ISAC Web site at: https://www.isac.world
Official publication of the Societe francaise d'allergologie (French society of allergy).ScopeThe Journal of Allergy and Hypersensitivity Diseases (JAHD) is a peer-reviewed, open-access journal in the fields of allergy and immunology. It covers all aspects of the fields, including clinical, educational, and translational research, associated with new technologies, epidemiology, public health and environmental aspects. JAHD is an international platform for promoting and disseminating findings in quality original articles, guidelines, reviews, and short communications to a wide audience.AimsThe JAHD supports modern and traditional approaches and public health strategies to improve the quality care of patients with allergy, asthma and hypersensitivity. An international team of experts counts as part of the editorial board and reviewers, who ensure dynamic peer-review and timely high impact scientific publications.ContentAll JAHD content will be peer-reviewed. The journal welcomes original articles covering the spectrum of conditions managed by allergists in clinical practice, such as:anaphylaxisdrug-related allergyfood and insect sting allergic and hypersensitivity conditionsallergic and hypersensitivity conditions affecting the eyesskin and respiratory tract conditionseosinophilic and mast cell disordersepidemiological, environmental, mechanistic, and diagnostic researchThe JAHD will present results from these areas in original papers, review articles and short communications. This research must advance the understanding of an allergic condition or medical treatment and contribute to improving the quality of care of patients with allergy, asthma, and hypersensitivity.Article typesThe JAHD will consider articles, reviews, technical notes and letters to the editors for publication, provided that the methodology and the scientific content are of high quality and the results have substantial clinical impact.Publication scheduleThe journal will be published in e-only format and 2 issues in the first year, 4 issues in the second, third and fourth years, and every 2 months in year 5 and after (6 issues per year). The journal will use a fast production workflow, with article-based publishing and article numbering.Editorial board and processesArticle quality will be assured by an international and gender-balanced editorial board nominated by the editor-in-chief.
As of 1 January 2019 the journal has been transferred back to the journal owner, Shanghai Hengrun Biomedical Technology Research Institute.Journal of Cellular Immunotherapy is an international journal in all areas of immunotherapy, including cellular immunology, non cellular immunotherapy (monoclonal antibodies), gene therapy, clinical immunology, hematology, oncology, allergology, rheumatology, and molecular biology, with special interest in cellular immunotherapy. Article types of this journal include full-length article, review article, short communication and editorial. The journal aims to provide the most complete and reliable source of information on current developments in the field. The emphasis will be on publishing quality articles rapidly and making them freely available to researchers worldwide. The journal will be essential reading for scientists and researchers who wish to keep abreast of the latest developments in the field.Research Areas include:AllergyAutoimmunityBiotechnologyClinical Laboratory ImmunologyGene TherapyHIVImmunodermatologyImmunohematologyImmunologic deficiency states and their reconstitutionImmunologic surveillance and tumor immunityImmunomodulationImmunotherapyLymphokines and cytokinesPrimary ImmunodeficiencyRheumatologyThymus and lymphocyte immunobiologyTransplantation immunologyTumor immunityVaccines